Cannabis médical et récréatif


#187

Je comprend très bien tout ceci.
Ce que je challenge c’est ton calcul basé sur ton ‘impression’ de ce que ça va être. Je pense aussi que le Canada est loin de se comparer aux USA. Au Canada, nous ne vivons pas la même oppression vis à vis ce marché versus ce que c’était aux USA pré-légalisation et même encore aujourd’hui dans certains états. Les consommateurs ici ont déjà beaucoup d’information et la production est déjà énorme en plus que la qualité y est. (on exporte beaucoup au USA illégalement parce que c’est beaucoup plus facile à partir d’ici et toléré jusqu’à un certain point) Dealer aux USA = très hauts risques de prison, donc le prix aussi de la rue est plus cher versus ici. Ce que je suis en train de dire au final, c’est que se procurer ce produit est facile au Canada et le prix est bas. La qualité est bonne alors pourquoi le consommateur va se tourner vers le même produit à 3 fois le prix?
Je serais 100% d’accord avec toi si le gouvernement avait décidé de permettre de créer une structure où on pourrait ouvrir des coffee shop, etc et promouvoir la consommation mais ce n’est pas le cas, on impose un paquet de règles sévères qui font en sorte que le côté récréatif est un peu diminué (au final le monde vont fumer sur leur balcon et dans le salon comme avant)
Tant mieux pour ceux qui font de l’argent avec ces titres, vraiment je suis content pour vous, sauf que comme Luc, je n’aime pas ta façon de tenter les gens d’investir avec de l’information
à moitié vérifiée…


#188

On verra bien dans 18 mois, on aura une image plus claire.


#189

BOOM

Heritage Cannabis Holdings To Build 3.0 Million Square Feet Of Cannabis Grow Space In Clearview, Ontario

2018-02-01 09:01 ET - News Release

(via TheNewswire)

Vancouver, B.C. / TheNewswire / February 1, 2018 - HERITAGE CANNABIS HOLDINGS CORPORATION (CSE: CANN) ( "Heritage " or Company ") is pleased to announce it has completed an accepted offer to acquire over 100 acres of farmland in Clearview Township, near Collingwood, Ontario.

Clearview is zoned agriculture and is approved for the cultivation of cannabis. There are approximately 85 acres of flat usable land suited for both indoor and outdoor cultivation. PhyeinMed Inc. (“PhyeinMed”), a Health Canada late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations), has a long-term growth strategy, separated into multiple phases, ultimately culminating in an operation with growing capacity of 3,000,000 square feet, capable of producing in excess of 300,000 kilograms of cannabis per year. The Company is anticipating a large demand for edibles and consumables, whether in candy or infused products, on legalization of this new market. Since the product needed for this market has different characteristics than the current planned cannabis flower products the Company is looking to produce, it will be targeting a combination of indoor and outdoor growth in an effort to be a low-cost producer.

PhyeinMed anticipates it will complete its final submission for a licence to produce cannabis following Phase 1 completion in mid-February, and immediately after obtaining licence for the current site in Falkland, British Columbia, we will apply for a second site for the property located in Ontario herein referred to as the Clearview cannabis facility.

The agreement to acquire the property was made by 1005477 BC Ltd., a wholly owned subsidiary of Heritage, which also owns 75% of PhyeinMed. Terms of the purchase include a total purchase price of $1.3 million with a targeted closing of June 30, 2018. The offer includes many subjects to the benefit of the buyer, including the award of a Licence to Produce Cannabis. The company will be providing a deposit of 10% of the purchase price immediately, with the remainder due at closing being paid by cash on hand.

Approval of the second site and licence permitting, construction is scheduled to begin in early 2019, with additional expansion to continue as demand grows.

“The expansion into Ontario is part of our long-term strategy of becoming a significant producer in the Canadian Cannabis marketplace.” commented Debra Senger, CEO of PhyeinMed “We are anticipating demand will outpace supply in the foreseeable future as legalization in Canada gets nearer to completion, and we intend to execute on our plan to ensure we can comfortably supply our customers with high quality products which will include all facets of the cannabis market for years to come”


#190

ouf c’est pas beau aujourd’hui,


#192

Quel revirement ce matin. De toute beauté !


#193

WEED a donné plus de 30% du bas de la journée


#194

Moi j en ai profité pour racheter du MMS ET CANN :sunglasses:


#195

Une autre grosse nouvelle pour $CANN.c

Vancouver, B.C. / TheNewswire / February 6, 2018 - HERITAGE CANNABIS HOLDINGS CORPORATION (CSE: CANN) ( "Heritage " or Company ") is pleased to announce that its subsidiary PhyeinMed Inc. (“PhyeinMed”), a Health Canada late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations), has initiated the process to apply for three cannabis retail store licences in Alberta.

PhyeinMed has contracted Cannabis Compliance Inc. to consult on the applications, working with Heritage advisory board member Michele Cadario, and PhyeinMed CEO Debra Senger. The applications are being created so they will be ready to be submitted immediately, once all levels of government in Alberta have approved and finalized their individual stipulations.

The retail store outlets are part of the long-term sales strategy being executed by the Company in an effort to increase brand awareness, and provide opportunities to market future products or brands which the company may choose to associate with. PhyeinMed has identified potential locations for these retail outlets, and will look to execute on these leases as soon as local governments approve.

“As we prepare to receive our Production Licence in the very near future, we continue to take steps to move our company’s sales and marketing plan forward” says Jagdip Bal, CEO of Heritage “as Provincial governments provide more details on how public distribution will work, we will adjust our plan accordingly. This Alberta retail strategy fits well for our marketing efforts.”

About Heritage Cannabis Holdings Corporation

The Company is currently listed as a marijuana issuer having a 75% interest in PhyeinMed Inc, a Health Canada late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations). It is a parent and development company with strategic plans to continue to acquire Cannabis related companies.


#196

Pour ceux qui ont manqué l’entrevue avec Clint Sharples de Heritage Cannabis Holdings $CANN.c

Voici l’enregistrement:

Ca dure environ 40 minutes, excellente entrevue, beaucoup de détails. Il mentionne qu’ils sont environ à 4 semaines de recevoir la license.


#197

Les résultats de ACB viennent de sortir, ils sont excellents. CA donne une bonne idée de la direction du marché

On discutait du prix du gramme…j’avais avancé 7$ le gramme pour CANN…ACB a eu une moyenne à 8.36$ le gramme

Une marge brute de 73%

Les ventes ont augmenté de 201% par rapport à l’an dernier et 41% par rapport au dernier quart.

Le coût de production a diminué de 1.87$ à 1.41$ par gramme
Les frais de ventes ont également diminué de 2.16$ à 1.74$

https://www.stockwatch.com/News/Item.aspx?bid=Z-C:ACB-2566779&symbol=ACB&region=C&fmt=orig


#198

et on ne parle que du marché restreint qu’est le cannabis médical. Imaginez quand le récréationel sera de la partie à partir de cet été. Les profits seront énormes


#199

C’est vrai que ca peut donner une idée, mais en meme temps, je crois que la mention “medicale” a ce cannabis amene une valeur ajoutée que n’aura pas le cannabis récréatif.

L’eau pour usage médical se vendant dans les pharmacies est vraiment plus chere que l’eau pour usage “récréatif” dans les épiceries.:wink:


#200

#201

et si les ‘édibles’ et les huiles deviennent légales…ce n’est qu’une question de temps, les marges de profit seront encore plus élevées que la fleur de cannabis simple


#202

LCBO chooses Shopify to run online cannabis sales; more pot retail news expected
The Canadian Press

February 12, 2018
12:02 AM EST

TORONTO — The Ontario government has inked a deal to use Shopify Inc.’s e-commerce platform for cannabis sales online and in stores as part of its plan to be the province’s sole distributor of legal recreational marijuana.


#203

Si jamais ca interesse certains: webinar demain entre 12h et 13h
http://www.lesaffaires.com/evenements/webinaires/marche-du-cannabis--soyez-au-fait-de-levolution-des-reglementations/599777

“Faites le bilan de la réglementation, tous paliers gouvernementaux confondus, entourant le marché du cannabis. L’approche sera concrète et pratique afin que vous soyez à jour et préparés à vous tailler une place dans cette industrie qui évolue à vitesse grand V.”


#204

http://www.lapresse.ca/affaires/economie/agroalimentaire/201802/14/01-5153804-quatre-compagnies-fourniront-du-cannabis-a-la-saq.php


#205

Et des résultats excellents pour Canopy. Croissance de 123% des ventes trimestrielles et on parle seulement du cannabis médical. Les prochains 12 mois seront excitants pour l’industrie.


#206

Grosse nouvelle pour Pascal Biosciences PAS.v + 290%, malheureusement j’ai manqué le bateau aujourd’hui mais je le surveille si il se repli demain.

2018-02-21 09:30 ET - News Release

VANCOUVER, British Columbia and SEATTLE, Feb. 21, 2018 (GLOBE NEWSWIRE) – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today announced the Company has discovered certain cannabinoids that enhance the immunogenicity of tumor cells, rendering them more susceptible to recognition by the immune system. This discovery is important because the leading class of new cancer fighting agents, termed “checkpoint inhibitors”, activates the immune system to destroy cancer cells. Enhancing recognition of cancer cells with cannabinoids may greatly improve the efficacy of this drug class. Cannabinoids are the chemical compounds which give the cannabis plant its medicinal properties with over 100 different cannabinoids identified. There is a growing body of research demonstrating the effectiveness of cannabinoids in the treatment of cancer symptoms, including nausea, appetite enhancement, and pain management. However, Pascal is the first to identify a mechanism in which cannabinoids may provide a direct benefit in immunotherapy.

Tumor cells often arise in individuals, but they are usually recognized by the immune system and destroyed. The immune system identifies cells as either normal or dangerous in a process called immunosurveillance. Cells that have become cancerous are recognized by cytotoxic T cells, specialized immune cells that target and kill the tumor cell. However, some malignant cells, particularly metastatic cells, employ an immune escape strategy to subvert and avoid recognition and are not recognized and attacked by cytotoxic T cells. This allows the spread of tumor cells to other tissues, potentially leading to fatal disease.

Checkpoint inhibitors are recently approved drugs that activate the immune system to kill tumor cells. These drugs are commercially successful (Opdivo®, Keytruda®, and Yervoy® together had over $6B in 2017 sales) and more importantly, can cure patients with some types of cancer, but only a fraction of patients (generally less than half) respond to the drugs. There are currently many efforts to find drugs that will enhance the activity of checkpoint inhibitors, and Pascal has discovered cannabinoids that activate a key step for immune recognition.

University of British Columbia Professor Wilf Jefferies and his research team in the Michael Smith Laboratories have developed a proprietary assay to discover compounds that can increase immune recognition of tumor cells. Dr. Jefferies, the scientific founder of Pascal, and his team screened thousands of natural products and subsequently identified certain cannabinoid molecules which have the greatest potency in their assay. While different cannabinoids show numerous biological and pharmacological effects, this is the first demonstration of immune activation by individual cannabinoids. Scientists from both UBC and Pascal have demonstrated that specific cannabinoids have strong potency on both mouse and human cancer cells.

“We are very excited about this novel discovery,” commented Dr. Patrick Gray, CEO of Pascal Biosciences. “Cannabinoids typically have good pharmacological properties, as most have low toxicity and are easily absorbed into the blood, which are great advantages for drug development. In combination with immune checkpoint inhibitors, cannabinoids may significantly improve cancer care. We look forward to soon translating our results into clinical studies.”

ABOUT PASCAL BIOSCIENCES INC.
Pascal Biosciences, Inc. (PAS, formerly bioMmune Technologies Inc.) is a drug discovery and development company focused on harnessing the body’s immune system to fight cancer. The Company’s three significant technologies are:

Utilizing proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells;
Exploiting the regulation of specific calcium channels expressed by cells of the immune system. By regulating these calcium channels, immune activity can be controlled to combat cancers, infections and autoimmune diseases; and
Developing a therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukemia, the most common childhood leukemia, in collaboration with the University of New Mexico.
To learn more, visit: https://www.pascalbiosciences.com/.

On Behalf of the Board of Directors
Dr. Patrick W. Gray, President & CEO

Company Contact:
Dr. Patrick Gray
Tel: 206-650-6765

Investors:
invest@pascalbiosciences.com
Tel: 206-221-3443


#207

fermeture à 0.47$
Je le surveille pour un point d’entrée demain